

### RECRO

# Annual Shareholder Meeting Management Presentation April 20, 2021

This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "anticipate", "believe", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "will" and similar terms and phrases may be used to identify forward-looking statements in this presentation. Our operations involve risks and uncertainties, many of which are outside our control, and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct.

These forward-looking statements are subject to risks and uncertainties including, among other things, the extent to which the ongoing COVID-19 pandemic continues to disrupt the Company's operations and financial condition and the operations and financial condition of its customers; the Company's ability to manage costs and execute on its operational and budget plans, the Company's ability to achieve its financial goals; the Company's ability to operate under increased leverage and associated lending covenants; to pay its debt under its credit agreement; the Company's ability to maintain relationships, profitability and contracts with commercial partners, including the impact of changes in consumer demand for the products the Company manufactures for its commercial partners; the Company's ability to diversify and grow its business with new customers; customers' changing inventory requirements and manufacturing plans; customer and prospective customers decisions to move forward with our manufacturing services; average profitability, or mix, of the products we manufacture; or customers facing increasing or new competition.

These forward-looking statements should be considered together with the risks and uncertainties that may affect our business and future results included in our filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are based on information currently available to us, and we assume no obligation to update any forward-looking statements except as required by applicable law.

# **RECRO** / An Emerging CDMO with a Clear Path to Sustained Growth

- 30+ Years of Successful Commercial Manufacturing for Multiple Global Customers
  - End-to-End Capabilities Servicing Early Stage through Commercial Production
  - Unique Expertise Solving Complex Solid Oral Dose Formulation & Development Challenges
    - ANDA Ownership and Profit-Sharing Structure for Multiple Drug Assets
    - **State-of-the-Art, Newly Upgraded Facilities, Available Capacity**
    - Highly Experienced CDMO Management and Board
- **N**¥

RECRC

- Strong Regulatory Track Record Spanning Multiple Countries and Agencies
- **Re-Organized Company Poised for Growth and Diversification Success in Robust Market**

### Multiple Powerful Industry Tailwinds in the CDMO Market

2015-2020 CAGR \$51.1 \$48.2 \$45.4 6.1% \$42.6 \$40.3 \$38.0 6.0% 6.2% \$8.2 \$7.2 \$6.8 6.2% 2020 2015 2016 2017 2018 2019 28.8% 29.6% 30.4% 32.2% 33.1% Outsourced 31.3% CMC API Drug Product

Large and Growing CDMO Market<sup>(1)</sup>

Continued outsourced penetration as biotech and pharma sponsors recognize the value of CDMO services

(1) Source: William Blair Equity Research.

(2) Source: Biocentury, Pharmaprojects, FactSet, and William Blair Estimates.

(3) Source: QuintilesIMS / IQVIA.

RECRO

(\$ in billions)

Total %


**Drug Candidates by Therapeutic Compound** 

Small	Oligos	Large	ADCs	Others	Total
1,458	66	1,076	47	459	3,106
1,560	83	1,057	29	496	3,225
506	21	355	6	114	1,002
203	4	119		70	396
2,114	12	1,182	6	550	3,864
5,841	186	3,789	88	1,689	11,593
	1,458 1,560 506 203 2,114	1,458     66       1,560     83       506     21       203     4       2,114     12	1,458661,0761,560831,0575062135520341192,114121,182	1,458661,076471,560831,05729506213556203411922,114121,1826	1,458661,076474591,560831,057294965062135561142034119702,114121,1826550

Recro market focus is ~50% of total CDMO market

### **RECRO** / Customers That Start With Recro, Stay With Recro

Recro's capabilities across the product development value chain



#### **Quality and Regulatory Excellence**



Formulation Development



Analytical Services



Regulatory

Support

ytical



Manufacturing



Packaging and Logistics

Early Phase	
Late Phase &	
Commercial	



## **RECRO**<sup>•</sup> Looking Ahead – A Strategy for Growth

## **RECRO**<sup>•</sup> / Executing a Multi-Pronged CDMO Growth Strategy



### RECRC

### Reorganization to Improve Efficiencies and Strengthen Leadership

#### In 2020 and 2021, key appointments were made to Recro's leadership and board

- David Enloe was appointed president & CEO in December 2020
  - Multiple years experience as CEO of CDMOs globally
- James ("Jim") Miller was appointed to the Recro board of directors in February 2021
  - Industry thought leader and advisor
- Ryan Lake was appointed CFO in December 2020
  - Deep financial acumen in CDMO space

### Additional areas of reorganization

- Consolidated development and commercial operations to allow for improved visibility on the pipeline and to optimize resource allocation.
- Improved management of the supply chain, which is critical as Recro onboards multiple new customers and programs.
- Re-worked organizational structure to deploy commercial best practices across entire organization.
- Expanding business development team.

### RECRO

### Expanding and Diversifying our Customer Base

Expand existing	Expand existing	Increase productivity
commercial	development	of business
customer base:	customer base:	development:
<ul> <li>Add new commercial products</li> <li>Up-sell complementary services</li> </ul>	<ul> <li>Guide projects through product cycle maturation</li> <li>Add additional development projects</li> </ul>	<ul> <li>Mature and grow BD team in existing territories</li> <li>Add BD members in new territories</li> </ul>

✓ Leverage recently added capabilities to drive new customer demand

✓ Add incremental capabilities – organically and / or inorganically


### / Customer Growth and Diversification Strategy is Paying Dividends

 Prior to 2020, Recro focused principally on commercial programs

RECRO

- In 2020, clinical trial support services (CTS) business launched to service precommercial projects
- Strategic move served to both increase and diversify customer base
- Diversified customer base reduces dependency on individual programs and mitigates revenue fluctuations





# **RECRO**<sup>•</sup> / Strengthening Balance Sheet

- Amendments to Credit Facility
  - \$25 million reduction in debt principal balance, from ~\$125M to ~\$100M
  - 1.5 percent interest rate reduction
  - Provides additional flexibility with financial maintenance covenants through term of loan March 2023
    - Interest only (eliminated \$24 million of principal amortization payments)
    - Net cash leverage ratio 6.0x (debt-cash/EBITDA)
    - Minimum liquidity \$9 million
  - ~\$15 million in cash savings
  - Equity issuance of \$9 million shares of common stock priced at-the-market

Successful balance sheet strategies have allowed expanded investment in growth of technical and business development teams

### / Expansion of Capabilities and Competencies

• Recent Progress:

RECRO

- Facilities recently expanded to support expanding customer base,
  - Multiple validation activities underway
- Smaller scale,
- High Potency,
- Clinical trial support services and
- Evaluation of inorganic addition(s) of capabilities



# **RECRO**<sup>•</sup> / Early Progress in Each Key Strategic Area – More To Come

Strengthening leadership and organization

In 2020 and 2021, key CDMO executives appointed to leadership and board
Deploying best practices across entire organization

Expanding and diversifying customer base

<ul> <li>In 2020, launched clinical trials materials business to support early-stage customers</li> </ul>
<ul> <li>Commercial manufacturing business continues to grow</li> </ul>

Strengthening balance sheet

In 2021, restructured and reduced debt to improve balance sheet
Stronger balance sheet best positions company for organic and inorganic growth



Enhancing capabilities and competencies • Upgrading and expanding capabilities and competencies to best support clinical stage projects, expanding commercial programs and high value technology transfers and validations

#### RECRO Strengthened Organization Creates Path To Sustained Growth

- **30+ Years of Successful Commercial Manufacturing for Multiple Global Customers** 
  - End-to-End Capabilities Servicing Early Stage through Commercial Production
  - Unique Expertise Solving Complex Solid Oral Dose Formulation & Development B Challenges
    - ANDA Ownership and Profit-Sharing Structure for Multiple Drug Assets
    - State-of-the-Art, Newly Upgraded Facilities, Available Capacity
    - **Highly Experienced CDMO Management and Board**

RECRC

- **Strong Regulatory Track Record Spanning Multiple Countries and Agencies**
- **Re-Organized Company Poised for Growth and Diversification Success in Robust Market**



### RECRO

# Annual Shareholder Meeting Management Presentation April 20, 2021